Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTC004 plus Toripalimab in IO-resistant solid tumors
NCT06490068Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of LTC004 in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jun 2024; status: recruiting.
02
Drugs
LTC004
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06490068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490068.